Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason C Sluzevich

Showing results (51-60 of 51) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 51 results.
Lancet (London, England)|January 11, 2025
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trialDavid Fiorentino, Aaron R Mangold, Victoria P Werth, et al.
Pageof 6

Showing results (51-60 of 51) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 51 results.
Lancet (London, England)|January 11, 2025
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trialDavid Fiorentino, Aaron R Mangold, Victoria P Werth, et al.
Pageof 6